Summary SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19, making
them a focus of vaccine design. A safety concern regarding SARS-CoV-2 antibodies is …

Summary SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern
regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 …

The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …

The high transmissibility and rapid global spread of SARS-CoV-2 since 2019 has led to a
huge burden on healthcare worldwide. Anti-SARS-CoV-2 neutralizing antibodies play an …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …

Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of
antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector …

The COVID-19 pandemic is a major threat to global health for which there are only limited
medical countermeasures, and we lack a thorough understanding of mechanisms of …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …